KR102790127B1 - Egfr 돌연변이와 관련된 암을 치료하는 조성물 및 방법 - Google Patents

Egfr 돌연변이와 관련된 암을 치료하는 조성물 및 방법 Download PDF

Info

Publication number
KR102790127B1
KR102790127B1 KR1020207036949A KR20207036949A KR102790127B1 KR 102790127 B1 KR102790127 B1 KR 102790127B1 KR 1020207036949 A KR1020207036949 A KR 1020207036949A KR 20207036949 A KR20207036949 A KR 20207036949A KR 102790127 B1 KR102790127 B1 KR 102790127B1
Authority
KR
South Korea
Prior art keywords
hours
plinabulin
pharmaceutical composition
tumor
minutes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207036949A
Other languages
English (en)
Korean (ko)
Other versions
KR20210015875A (ko
Inventor
란 황
조지 케네스 로이드
Original Assignee
비욘드스프링 파마수티컬스, 인코포레이티드.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비욘드스프링 파마수티컬스, 인코포레이티드. filed Critical 비욘드스프링 파마수티컬스, 인코포레이티드.
Publication of KR20210015875A publication Critical patent/KR20210015875A/ko
Application granted granted Critical
Publication of KR102790127B1 publication Critical patent/KR102790127B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020207036949A 2018-06-01 2019-05-30 Egfr 돌연변이와 관련된 암을 치료하는 조성물 및 방법 Active KR102790127B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862679619P 2018-06-01 2018-06-01
US62/679,619 2018-06-01
PCT/US2019/034726 WO2019232257A1 (en) 2018-06-01 2019-05-30 Composition and method of treating cancer associated with egfr mutation

Publications (2)

Publication Number Publication Date
KR20210015875A KR20210015875A (ko) 2021-02-10
KR102790127B1 true KR102790127B1 (ko) 2025-04-03

Family

ID=68696755

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207036949A Active KR102790127B1 (ko) 2018-06-01 2019-05-30 Egfr 돌연변이와 관련된 암을 치료하는 조성물 및 방법

Country Status (11)

Country Link
US (2) US20210161888A1 (enExample)
EP (1) EP3801524B1 (enExample)
JP (1) JP7500438B2 (enExample)
KR (1) KR102790127B1 (enExample)
CN (1) CN112543636B (enExample)
AU (1) AU2019278886B2 (enExample)
CA (1) CA3101612A1 (enExample)
DK (1) DK3801524T3 (enExample)
ES (1) ES3060133T3 (enExample)
MX (1) MX420412B (enExample)
WO (1) WO2019232257A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202008673WA (en) 2015-03-06 2020-10-29 Beyondspring Pharmaceuticals Inc Method of treating cancer associated with a ras mutation
US10155748B2 (en) 2015-07-13 2018-12-18 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
JP2019511565A (ja) 2016-02-08 2019-04-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド ツカレゾールまたはそのアナログを含む組成物
AU2017278245B2 (en) 2016-06-06 2022-09-15 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing neutropenia
EP3565812B1 (en) 2017-01-06 2023-12-27 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
KR20240110997A (ko) 2017-02-01 2024-07-16 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증의 감소 방법
EP3743074A4 (en) 2018-01-24 2021-12-15 Beyondspring Pharmaceuticals Inc. COMPOSITION AND METHOD FOR REDUCING THROMBOCYTOPENIA BY THE ADMINISTRATION OF PLINABULINE
WO2022216908A1 (en) 2021-04-09 2022-10-13 Beyondspring Pharmaceuticals, Inc. Therapeutic compositions and methods for treating tumors
CN113456643B (zh) * 2021-08-11 2022-04-01 遵义医科大学 一种含普那布林的药物组合及其应用
KR20240082379A (ko) * 2021-10-03 2024-06-10 시스트이뮨, 인코포레이티드 암 치료 방법 및 이의 약제학적 조성물
CN117860672A (zh) * 2022-10-11 2024-04-12 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法
KR20260019493A (ko) * 2023-06-02 2026-02-10 비욘드스프링 파마수티컬스, 인코포레이티드. 종양 병용 요법 및 사용 방법
CN120682197A (zh) * 2024-03-19 2025-09-23 大连万春布林医药有限公司 普那布林的盐晶型

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60316688T2 (de) * 2002-08-02 2008-07-17 Nereus Pharmaceuticals, Inc., San Diego Dehydrophenylahistine und analoge davon sowie ein verfahren zur herstellung von dehydrophenylahistinen und analogen davon
US20120114658A1 (en) * 2009-09-15 2012-05-10 John Ryan Treatment of cancer
CA2939165A1 (en) * 2009-09-15 2011-03-24 Cerulean Pharma Inc. A cdp-camptothecin conjugate, particle or composition and uses thereof
LT2958943T (lt) * 2013-02-20 2020-01-27 The Trustees Of The University Of Pennsylvania Vėžio gydymas, naudojant humanizuotą anti-egfrviii chimerinio antigeno receptorių
KR20240110996A (ko) * 2015-02-12 2024-07-16 비욘드스프링 파마수티컬스, 인코포레이티드. 면역 관문 저해제와 조합한 플리나불린의 용도
SG10202008673WA (en) * 2015-03-06 2020-10-29 Beyondspring Pharmaceuticals Inc Method of treating cancer associated with a ras mutation
NZ778329A (en) * 2017-03-13 2026-03-27 Beyondspring Pharmaceuticals Inc Compositions of plinabulin and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Clinical Oncology, 35(7), Suppl. 1, 139. 2017.*

Also Published As

Publication number Publication date
KR20210015875A (ko) 2021-02-10
EP3801524A4 (en) 2022-03-02
MX420412B (es) 2025-02-10
CN112543636B (zh) 2024-03-01
AU2019278886B2 (en) 2025-03-20
AU2019278886A1 (en) 2020-12-24
JP7500438B2 (ja) 2024-06-17
DK3801524T3 (da) 2026-02-02
US20250375440A1 (en) 2025-12-11
US20210161888A1 (en) 2021-06-03
CA3101612A1 (en) 2019-12-05
CN112543636A (zh) 2021-03-23
JP2021525768A (ja) 2021-09-27
MX2020012799A (es) 2021-03-25
EP3801524A1 (en) 2021-04-14
ES3060133T3 (en) 2026-03-25
WO2019232257A1 (en) 2019-12-05
EP3801524B1 (en) 2025-11-05

Similar Documents

Publication Publication Date Title
US20250375440A1 (en) Composition and method of treating cancer associated with egfr mutation
US12343344B2 (en) Pharmaceutical combination comprising TNO155 and ribociclib
US20160129003A1 (en) Pharmaceutical Combinations
AU2017329090A1 (en) Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
AU2012333092B2 (en) Synergistic combinations of PI3K- and MEK-inhibitors
US10765682B2 (en) Apilimod for use in the treatment of melanoma
WO2015097621A2 (en) Pharmaceutical combinations
EP2885003A1 (en) Combination of pi3k inhibitor and c-met inhibitor
WO2019053595A1 (en) INHIBITORS OF PROTEIN KINASE C FOR THE TREATMENT OF CHOROIDAL MELLANOMA
US9446043B2 (en) Pharmaceutical combinations
EP4203963B1 (en) Combination therapy of naporafenib and trametinib for use in the treatment of sarcoma
HK40038993A (en) Composition and method of treating cancer associated with egfr mutation
US20220331318A1 (en) Use of an mdm2 inhibitor for the treatment of myelofibrosis
HK1215789B (en) Pharmaceutical combinations

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20201222

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220518

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20241202

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250221

PG1601 Publication of registration